{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:56:04Z","timestamp":1790916964166,"version":"4.1.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Peritoneal neuroendocrine carcinoma(NEC) is primarily metastatic, with primary cases being exceedingly rare. The relationship between alpha-fetoprotein(AFP) and neuroendocrine carcinoma remains unclear. In this report, we present a patient with peritoneal neuroendocrine carcinoma who exhibited significantly elevated AFP levels. Extensive evaluation revealed no obvious primary site outside the peritoneum; however, occult gastrointestinal origin could not be entirely excluded. The tumor was thus classified as NEC of unknown primary, with a presumed primary peritoneal origin. The findings from this case suggest that markedly elevated AFP may be associated with aggressive tumor behavior and could serve as a potential marker for monitoring disease activity in peritoneal NECs, a hypothesis that warrants further investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 51-year-old man with massive ascites and elevated AFP levels was admitted to the hospital. Liver enhanced magnetic resonance imaging and gastrointestinal endoscopy did not reveal any space-occupying lesions, while abdominal puncture did not detect tumor cells. The patient\u2019s whole-body PET-CT revealed extensive peritoneal thickening and increased FDG metabolism. Subsequent laparoscopic exploration revealed numerous nodules and masses of varying sizes with a firm texture in the greater omentum, small intestine surface, mesentery, and parietal peritoneum. Immunohistochemistry of the omentum demonstrated positive results for AE1\/AE3, Syn, CgA, and AFP, leading to a final diagnosis of large cell NEC of unknown primary, with a presumed primary peritoneal origin. Due to the presence of multiple peritoneal nodules, radical surgery was not feasible, and EP combined with camrelizumab was initiated. AFP levels showed an overall progressive increase, peaking at 5315 ng\/mL on May 25, with a slight subsequent decline to 4948.4 ng\/mL on June 20. Unfortunately, the patient discontinued chemotherapy after two cycles due to severe nausea and vomiting; he subsequently succumbed to the disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We propose the hypothesis that dynamic changes in AFP levels could reflect tumor burden and treatment response in a subset of AFP-producing NECs. However, this hypothesis requires validation in larger cohort studies. It is also important to distinguish its potential role as a monitoring biomarker from an established prognostic biomarker.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1962119","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:40:33Z","timestamp":1790916033000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Peritoneal neuroendocrine carcinoma of unknown primary with markedly elevated alpha-fetoprotein: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Jie","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital","place":["Lishui, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital","place":["Lishui, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Que","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital","place":["Lishui, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibo","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital","place":["Lishui, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bitong","family":"He","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital","place":["Lishui, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinxia","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital","place":["Lishui, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"OC3","DOI":"10.1530\/endoabs.52.oc3","article-title":"Incidence and prevalence of neuroendocrine tumors in England","volume":"52","author":"Genus","year":"2017","journal-title":"Endocrine Abstracts"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.15.4377","article-title":"One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/s1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-109-5-364","article-title":"Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity","volume":"109","author":"Hainsworth","year":"1988","journal-title":"Ann Intern Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0046-8177(84)80174-4","article-title":"Primary carcinoid tumor of the mesentery","volume":"15","author":"Barnardo","year":"1984","journal-title":"Hum Pathol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"108517","DOI":"10.1016\/j.ijscr.2023.108517","article-title":"Primary mesenteric neuroendocrine tumor: Case report","volume":"109","author":"Gonz\u00e1lez-Mu\u00f1oz","year":"2023","journal-title":"Int J Surg Case Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/0090-4295(93)90249-a","article-title":"Renal angiomyolipoma associated with neurofibromatosis and primary carcinoid of mesentery","volume":"41","author":"Stone","year":"1993","journal-title":"Urology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"662","DOI":"10.4103\/0973-1482.138108","article-title":"Primary synchronous mesenteric neuroendocrine tumors: Report of a rare case with review of literature","volume":"11","author":"Kamath","year":"2015","journal-title":"J Cancer Res Ther"},{"key":"B11","article-title":"Carcinoid tumor presenting as a primary mesenteric mass: a case report and review of the literature","volume":"68","author":"Yamanuha","year":"2009","journal-title":"Hawaii Med J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3919\/jjsa.75.467","article-title":"A case of resected primary jejunal mesenteric carcinoid tumor","volume":"75","author":"Jida","year":"2014","journal-title":"Nihon Rinsho Geka Gakkai Zasshi"},{"key":"B13","doi-asserted-by":"publisher","first-page":"101465","DOI":"10.1016\/j.clinre.2020.05.013","article-title":"Primary mesenteric neuroendocrine tumour","volume":"45","author":"Lee","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s12328-016-0701-4","article-title":"Primary mesenteric neuroendocrine tumor that changed its internal composition from cystic to solid: a case report","volume":"10","author":"Yasuda","year":"2017","journal-title":"Clin J Gastroenterol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s40792-022-01482-x","article-title":"Primary grade 2 neuroendocrine tumor of the ileal mesentery: a case report","volume":"8","author":"Morishita","year":"2022","journal-title":"Surg Case Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45465","article-title":"Cracking the code of a rare colonic mesentery gastrointestinal neuroendocrine tumor disguised as chronic gastroenteritis: The critical art of timely detection","volume":"15","author":"Achong","year":"2023","journal-title":"Cureus"},{"key":"B17","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1159\/000490522","article-title":"Primary mesenteric carcinoid tumor presenting with carcinoid syndrome","volume":"12","author":"Shogbesan","year":"2018","journal-title":"Case Rep Gastroenterol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s40792-021-01217-4","article-title":"Neuroendocrine tumor arising from the greater omentum treated with laparoscopic tumor resection: a case report","volume":"7","author":"Terai","year":"2021","journal-title":"Surg Case Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e258366","DOI":"10.1136\/bcr-2023-258366","article-title":"Neuroendocrine tumour of the lesser omentum","volume":"16","author":"Babu","year":"2023","journal-title":"BMJ Case Rep"},{"key":"B20","article-title":"WHO classification of tumours of the digestive system","author":"Kindblom","year":"2010"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1159\/000503772","article-title":"Diagnostic approaches to neuroendocrine neoplasms of unknown primary site","volume":"110","author":"Berner","year":"2020","journal-title":"Neuroendocrinology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1159\/000369275","article-title":"Grading of neuroendocrine neoplasms: mitoses and Ki-67 are both essential","volume":"100","author":"van Velthuysen","year":"2014","journal-title":"Neuroendocrinology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000445761","article-title":"The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: Morphological differentiation and proliferation identify different prognostic categories","volume":"104","author":"Milione","year":"2017","journal-title":"Neuroendocrinology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i36.6055","article-title":"Liver metastasis is the only independent prognostic factor in AFP-producing gastric cancer","volume":"19","author":"Hirajima","year":"2013","journal-title":"World J Gastroenterol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000023326","article-title":"Dynamic change in serum alpha-fetoprotein level predicts treatment response and prognosis of alpha-fetoprotein-producing gastric cancer","volume":"99","author":"Wang","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i2.266","article-title":"Predictive and prognostic value of serum AFP level and its dynamic changes in advanced gastric cancer patients with elevated serum AFP","volume":"24","author":"Wang","year":"2018","journal-title":"World J Gastroenterol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.635537","article-title":"The clinicopathological characteristics of alpha-fetoprotein-producing adenocarcinoma of the gastrointestinal tract-a single-center retrospective study","volume":"11","author":"Kong","year":"2021","journal-title":"Front Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2017.04.005","article-title":"Alpha-fetoprotein is a significant prognostic factor for gastric cancer: Results from a propensity score matching analysis after curative resection","volume":"43","author":"Reim","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604435","article-title":"Alpha-fetoprotein and human chorionic gonadotrophin-beta as prognostic markers in neuroendocrine tumour patients","volume":"99","author":"Shah","year":"2008","journal-title":"Br J Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-20-3391","article-title":"Primary neuroendocrine carcinoma of the breast with markedly elevated alpha-fetoprotein: a case report","volume":"10","author":"Wang","year":"2021","journal-title":"Transl Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-1374922\/v1","article-title":"An ovarian large-cell neuroendocrine carcinoma accompanied by clear cell carcinoma with specific high level of AFP: Case report and review of the literature","volume":"14","author":"Qiu","year":"2022","journal-title":"Cancer Manag Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3892\/mco.2021.2248","article-title":"Anterior mediastinal large cell neuroendocrine carcinoma with elevated AFP: A case report and review","volume":"14","author":"Komisarof","year":"2021","journal-title":"Mol Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00795-013-0035-y","article-title":"Alpha-fetoprotein-producing clear cell carcinoma of the gallbladder with neuroendocrine differentiation","volume":"47","author":"Sentani","year":"2014","journal-title":"Med Mol Morphol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03331-6","article-title":"Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma","volume":"146","author":"Zheng","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/pas.0b013e31823aafec","article-title":"Histologic and immunohistochemical analyses of \u03b1-fetoprotein--producing cancer of the stomach","volume":"36","author":"Kinjo","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.756363","article-title":"The dynamic changes of AFP from baseline to recurrence as an excellent prognostic factor of hepatocellular carcinoma after locoregional therapy: A 5-year prospective cohort study","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2026.1778029","article-title":"Beyond conventional biomarkers: the role of alpha-fetoprotein in gastroenteropancreatic neuroendocrine neoplasms","volume":"17","author":"La Salvia","year":"2026","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B38","first-page":"32","article-title":"Chinese Anti-Cancer Association guidelines for the diagnosis and treatment of neuroendocrine neoplasms (2022 edition)","author":"Jie","year":"2022","journal-title":"China Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"6753","DOI":"10.1038\/s41467-024-50969-8","article-title":"Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 neuroendocrine neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913)","volume":"15","author":"Riesco-Martinez","year":"2024","journal-title":"Nat Commun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.958905","article-title":"First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: Study protocol for a prospective, multicenter, phase II study","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1962119\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:40:43Z","timestamp":1790916043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1962119\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":40,"alternative-id":["10.3389\/fendo.2026.1962119"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1962119","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"article-number":"1962119"}}